ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

摘要:

Asthma is now recognised as a chronic inflammatory disease associated with increased airways responsiveness and episodic reversible airways obstruction. It is the most common chronic disease in children and its prevalence is increasing in most countries of the world. Current emphasis in treating paediatric patients with asthma is on preventing asthma-induced airways remodelling (changes in structure and function) and maximising lung growth with the intention of preventing fixed airways obstruction in adulthood. The advent of managed care has helped to promote optimal disease management strategies which look beyond drug therapy to preventative measures. Details of a successful disease management programme for children with asthma were presented at The Disease Management Congress*[New York, US; June 1997].

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

摘要:

Genentech and Boehringer Ingelheim are joining forces to develop the second-generation plasminogen activator TNK [TNK-tPA], which is their own recombinant version of the thrombolytic drug alteplase. Like the other recombinant agents (reteplase, lanoteplase and monteplase*), TNK has a longer half-life than alteplase. This means that it can be given as a single bolus in the acute-care setting. Two trials of the new thrombolytic agent were presented at the 19th Congress of the European Society of Cardiology [Stockholm, Sweden; August 1997], along with the results of 2 new studies of potential adjunctive therapies to thrombolysis.

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS